You searched for Lymphoma

News and Trends 18 Aug 2022

FDA lifts partial clinical hold on Curis lymphoma study

…FLT3, a known oncologic driver, which may provide additional benefit in patients with AML and MDS. About TakeAim lymphoma The TakeAim Lymphoma study is a phase 1/2 open-label, dose escalation,…

August 18, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Apr 2023

FDA approves Genentech’s lymphoma drug

…with gemcitabine and oxaliplatin in patients with R/R DLBCL. About diffuse large B-cell lymphoma Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL), accounting for…

April 20, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 10 Oct 2022

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug

…studies on hematologic malignancies and autoimmune diseases, including third-line mantle cell lymphoma (MCL), third-line acute lymphoblastic leukemia (ALL), frontline and second-line large B-cell lymphoma (LBCL), and systemic lupus erythematosus (SLE)….

October 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Genentech lymphoma treatment gets FDA approval

…of rituximab. The primary outcome measure is progression-free survival (PFS) as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. About diffuse large B-cell lymphoma Diffuse large…

August 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Jul 2022

License submitted to FDA for drug to help those with large B-cell lymphoma

A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company…

July 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

…to investigate the safety of CTH-001 in this patient population. Cutaneous T-cell lymphoma Cutaneous T-cell lymphoma is the term applied to a family of non-Hodgkin lymphoma cancers that affect the…

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

…or refractory peripheral T/NK cell lymphoma. The peripheral T cell lymphomas (PTCL) constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults. Strategic collaboration This single arm study…

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 14 Nov 2017

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form…

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2022

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the…

November 2, 2022 - 3 minutesmins - By Liza Laws

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

…both tumor cells and healthy cells. AFM13, on the other hand, is designed to treat CD30-positive malignancies including Hodgkin lymphoma (HL) and T-cell lymphoma (TCL – one of the deadliest…

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 2 Aug 2022

Cellectis gets green light for non-Hodgkin lymphoma trial

…for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to begin enrolling patients in the NatHaLi-01 study in the second half of the year. Enhancing tumor…

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

First patient dosed in China trial with drug to treat non-Hodgkin lymphoma

The dosing of the first patient at a clinical trial in China for patients with relapsed/refractory non-Hodgkin lymphoma (NHL) was announced yesterday (September 7). CASI Pharmaceuticals and BioInvent International AB…

September 8, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Lymphoma

FDA lifts partial clinical hold on Curis lymphoma study

FDA approves Genentech’s lymphoma drug

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug

Genentech lymphoma treatment gets FDA approval

License submitted to FDA for drug to help those with large B-cell lymphoma

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Cellectis gets green light for non-Hodgkin lymphoma trial

First patient dosed in China trial with drug to treat non-Hodgkin lymphoma

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!